Praxis Precision Medicines, Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Praxis Precision Medicines, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2019 to Q2 2024.
  • Praxis Precision Medicines, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$32.7M, a 4.77% increase year-over-year.
  • Praxis Precision Medicines, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$124M, a 21.1% increase year-over-year.
  • Praxis Precision Medicines, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$123M, a 42.4% increase from 2022.
  • Praxis Precision Medicines, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$214M, a 28.1% decline from 2021.
  • Praxis Precision Medicines, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$167M, a 170% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$124M -$32.7M +$1.64M +4.77% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$125M -$39.6M -$2.1M -5.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-13
Q4 2023 -$123M -$26.9M +$14.3M +34.7% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 -$138M -$24.6M +$19.3M +43.9% Jul 1, 2023 Sep 30, 2023 10-K 2024-03-05
Q2 2023 -$157M -$34.3M +$25.9M +43% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$183M -$37.5M +$31.3M +45.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-13
Q4 2022 -$214M -$41.2M +$17.4M +29.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 -$231M -$43.9M +$760K +1.7% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-05
Q2 2022 -$232M -$60.2M -$23.8M -65.4% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-05
Q1 2022 -$208M -$68.7M -$41.3M -151% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-05
Q4 2021 -$167M -$58.6M -$32.9M -128% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-07
Q3 2021 -$134M -$44.7M -$28.5M -176% Jul 1, 2021 Sep 30, 2021 10-K 2023-02-07
Q2 2021 -$106M -$36.4M -$24.8M -215% Apr 1, 2021 Jun 30, 2021 10-K 2023-02-07
Q1 2021 -$80.9M -$27.4M -$19M -229% Jan 1, 2021 Mar 31, 2021 10-K 2023-02-07
Q4 2020 -$61.8M -$25.7M Oct 1, 2020 Dec 31, 2020 10-K 2022-02-28
Q3 2020 -$16.2M -$5.61M -52.9% Jul 1, 2020 Sep 30, 2020 10-K 2022-02-28
Q2 2020 -$11.6M Apr 1, 2020 Jun 30, 2020 10-K 2022-02-28
Q1 2020 -$8.33M Jan 1, 2020 Mar 31, 2020 10-K 2022-02-28
Q3 2019 -$10.6M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.